A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GSK 189254A | GSK-189,254 is a H3 histamine receptor inverse agonist. It has subnanomolar affinity for the H3 receptor with Ki of 0.2nM. It possesses stimulant and nootropic effects and analgesic action suggesting a role for H3 receptors in pain processing in the spinal cord. No development was reported about Phase-II clinical trials for Narcolepsy in Europe. Uses: Narcolepsy. Alternative Names: 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-Pyridinecarboxamide. Grades: 98%. CAS No. 720690-73-3. Molecular formula: C21H25N3O2. Mole weight: 351.44. |  |
| GSK1904529A | GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC50s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1089283-49-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10524. |  |
| GSK199 | GSK199 is an orally active, reversible, and selective PAD4 inhibitor with an IC50 of 200 nM in the absence of calcium. GSK199 can be used for the research of rheumatoid arthritis[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1549811-53-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-103058. | |
| GSK-2018682 | GSK-2018682 is a potent and selective agonist of sphingosine-1-phosphate receptor (S1PR) subtype 1 that has the potential to treat multiple sclerosis (MS). Alternative Names: GSK2018682; GSK 2018682; GSK-2018682. UNII-NJL503AIJA; NJL503AIJA; 4-(4-(5-(5-chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl)-1H-indol-1-yl)butanoic acid. Grades: ≥98%. CAS No. 1034688-30-6. Molecular formula: C22H21ClN4O4. Mole weight: 440.884. | |
| GSK2033 | GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively. Uses: Scientific research. Category: Signaling pathways. CAS No. 1221277-90-2. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108688. | |
| GSK205 | GSK205 is a potent, selective TRPV4 antagonist with an IC50 of 4.19? μM for inhibiting TRPV4-mediated Ca2+ influx[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1263068-83-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-120691A. | |
| GSK215 | GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC50 of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2743427-26-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg. Product ID: HY-132296. | |
| GSK2193874 | GSK2193874 is an orally active, potent, and selective TRPV4 antagonist with IC50s of 2 nM and 40 nM for rTRPV4 and hTRPV4[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1336960-13-4. Pack Sizes: 10 mM * 1 mL in DMSO; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100720. | |
| GSK2193874 | GSK2193874 is a potent, orally active and specific antagonist of TRPV4 ion channels (IC50 values 2 and 40 nM for rat and human receptors, respectively). GSK2193874 is selective over a panel of ~200 human receptors, channels and enzymes. Alternative Names: GSK2193874; GSK 2193874; GSK-2193874; GSK2193874A; GSK 2193874A; GSK-2193874A; 7-bromo-N-(1-phenylcyclopropyl)-3-[(4-piperidin-1-ylpiperidin-1-yl) methyl]-2-[3-(trifluoromethyl)phenyl]quinoline-4-carboxamide. CAS No. 1336960-13-4. Molecular formula: C37H38BrF3N4O. Mole weight: 691.62. | |
| GSK2194069 | GSK2194069 is a potent inhibitor of β-ketoyl reductase (KR) of fatty acid synthase (FASN), with an IC50 value of 7.7 nM. GSK2194069 shows specifically inhibitory effect on FAS expressing cancer cells, by acting potent efficacy on acetoacetyl-CoA, NADPH with IC50 or Ki values of 4.8 nM and 5.6 nM, respectively[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1332331-08-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12325. | |
| GSK2239633A | GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [125I]-TARC to human CCR4 with a pIC50 of 7.96. Uses: Scientific research. Category: Signaling pathways. CAS No. 1240516-71-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100183. | |
| GSK2256098 | GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Uses: Scientific research. Category: Signaling pathways. CAS No. 1224887-10-8. Pack Sizes: 10 mM * 1 mL in DMSO; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100498. | |
| GSK-2256098 | GSK2256098, also known as GTPL7939, is a focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Alternative Names: GSK2256098; GSK 2256098; GSK-2256098; GTPL7939; GTPL-7939; GTP L7939. Grades: 98%. CAS No. 1224887-10-8. Molecular formula: C20H23ClN6O2. Mole weight: 414.89. | |
| GSK2256294A | GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH). GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC50s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: GSK 2256294. CAS No. 1142090-23-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-19644. | |
| GSK2256294A | GSK2256294A, an effective inhibitor of human soluble epoxide hydrolase(sEH), was developed by GSK and still under Phase I trial in Chronic obstructive pulmonary disease. IC50: 27pM. Uses: Gsk2256294a is an effective inhibitor of human soluble epoxide hydrolase(seh). Alternative Names: GSK2256294; GSK-2256294; GSK 2256294; GSK-2256294A; GSK 2256294A. Grades: 98%. CAS No. 1142090-23-0. Molecular formula: C21H24F3N7O. Mole weight: 447.46. | |
| GSK2292767 | GSK2292767 is a potent and selective inhibitor of PI3Kδ, with a pIC50 of 10.1. GSK2292767 showing greater than 500-fold selective over the other PI3K isoforms. GSK2292767 can be used for the research of respiratory disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1254036-66-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg. Product ID: HY-15280. | |
| GSK2334470 | GSK2334470 is a potent 3-phosphoinositide-dependent protein kinase (PDK1) inhibitor (IC50 ~ 10 nM), which does not suppress the activity of 93 other protein kinases including 13 AGC-kinases most related to PDK1 at 500-fold higher concentrations. GSK2334470 also inhibited T-loop phosphorylation and activation of Akt. GSK2334470 will be a useful tool for delineating the roles of PDK1 in biological processes. Alternative Names: GSK2334470; GSK2334470; GSK2334470. Grades: 0.98. CAS No. 1227911-45-6. Molecular formula: C25H34N8O. Mole weight: 462.602. | |
| GSK2334470 | GSK2334470 is a highly specific and potent inhibitor of PDK1 with an IC50 of 10 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1227911-45-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-14981. | |
| GSK239512 | GSK239512 is a potent and brain penetrated H3 receptor antagonist. GSK239512 can be used for the research of mild-to-moderate Alzheimer's disease (AD)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 720691-69-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-106000. | |
| GSK2556286 | GSK2556286 (GSK286) is an orally active and cholesterol-dependent Mycobacterium tuberculosis inhibitor. GSK2556286 inhibits Mycobacterium tuberculosis inside infected macrophages (IC50 = 0.07 μM in THP-1 cells), in the presence of cholesterol. GSK2556286 acts via Rv1625c, a membrane-bound adenylyl cyclase in Mycobacterium tuberculosis. GSK2556286 is an Rv1625 agonist leading to increased cAMP and reduced cholesterol metabolism. GSK2556286 can be studied in research for antitubercular purposes[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: GSK286. CAS No. 1210456-20-4. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-147017. | |
| GSK256066 | GSK256066 is a selective and high-affinity phosphodiesterase 4 (PDE4) inhibitor, with an IC50 of 3.2 pM for PDE4B. GSK256066 is developed for the research of chronic obstructive pulmonary disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 801312-28-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10469. | |
| GSK256073 | GSK256073 Inhibitor. Uses: Scientific use. Product Category: T15432. CAS No. 862892-90-8. |  |
| GSK256073 | GSK256073 is a potent, selective and orally active G-protein coupled receptor 109A (GPR109A) agonist and a long-lasting and non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) full agonist with a pEC50 of 7.5 for human HCA2. It acutely improves glucose homeostasis by inhibiting lipid breakdown and has the potential to study type 2 diabetes mellitus (T2DM) and dyslipidemia. Alternative Names: 8-Chloro-3-pentyl-1H-purine-2,6(3H,7H)-dione; 1H-Purine-2,6-dione, 8-chloro-3,9-dihydro-3-pentyl-; 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione; 8-Chloro-6-hydroxy-3-pentyl-3,9-dihydro-2H-purin-2-one. Grades: ≥95%. CAS No. 862892-90-8. Molecular formula: C10H13ClN4O2. Mole weight: 256.69. | |
| GSK256073 | GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia[1][2]. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2. Uses: Scientific research. Category: Signaling pathways. CAS No. 862892-90-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-119222. | |
| GSK2578215A | Potent leucine-rich repeat kinase 2 (LRRK2) inhibitor (IC50 values are 8.9 and 10.1nm respectively for LRRK2[G2019S] mutant and wild-type LRRK2 respectively). Displays selectivity for LRRK2 against a panel of 460 other kinases. Blocks Ser910 and Ser935 phosphorylation in vitro and in peripheral tissues in vivo. Brain penetrant. Group: Biochemicals. Alternative Names: 5-(2-Fluoro-4-pyridinyl)-2-(phenylm ethoxy)-N-3-pyridinylbenzamide. Grades: Highly Purified. CAS No. 1285515-21-0. Pack Sizes: 10mg, 25mg. US Biological Life Sciences. |  Worldwide |
| GSK2606414 | GSK2606414 is an orally available, potent, and selective PERK inhibitor with IC50 of 0.4 nM, displaying at least 100-fold selectivity over the other EIF2AKs assayed. GSK2606414 impairs GANT-61 induced autophagy in NB cells with MYCN amplification. GSK2606414 exacerbates ER stress-induced apoptosis in HCT116 cells while reduces the apoptosis in SIL1 KD HeLa cells. Group: Inhibitors. CAS No. 1337531-36-8. Pack Sizes: 5mg. Product ID: S7307. Formula: C24H20F3N5O. Smiles: CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F. Storage Conditions: 2 years -80 in solvent. |  United States; Europe |
| GSK2606414 | GSK2606414 is a cell-permeable and orally available protein kinase R-like endoplasmic reticulum (ER) kinase (PERK) inhibitor with an IC50 of 0.4 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1337531-36-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg; 500 mg; 1 g. Product ID: HY-18072. | |
| GSK 2606414 | GSK 2606414. Group: Biochemicals. Alternative Names: 7-Methyl-5-[1-[[3- (trifluoromethyl) phenyl]acetyl]-2, 3-dihydro-1H-indol-5-yl]-7H-pyrrolo[2, 3-d]pyrimidin-4-amine. Grades: Highly Purified. CAS No. 1337531-36-8. Pack Sizes: 1mg. Molecular Formula: C24H22F3N5O, Molecular Weight: 453.46. US Biological Life Sciences. | Worldwide |
| GSK 2606414 | GSK 2606414 is a potent and selective PERK inhibitor that suppresses PERK activation in cells and inhibits the growth of a human tumor xenograft in mice. Protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small-molecule inhibitors. Alternative Names: GSK2606414; GSK-2606414; GSK 2606414; GSK PERK Inhibitor. 1-(5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-indolin-1-yl)-2-(3-(trifluoromethyl)phenyl)ethanone. Grades: 98%. CAS No. 1337531-36-8. Molecular formula: C24H20F3N5O. Mole weight: 451.453. | |
| GSK2636771 | GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3Kβ with a Ki of 0.89 nM and an IC50 of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms. Uses: Scientific research. Category: Signaling pathways. CAS No. 1372540-25-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15245. | |
| GSK2636771 | GSK2636771 is an orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt / mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt / mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells. Uses: Antineoplastic agents. Alternative Names: GSK2636771; GSK-2636771; GSK 2636771. CAS No. 1372540-25-4. Molecular formula: C22H22F3N3O3. Mole weight: 433.431. | |
| GSK264220A | GSK264220A is a potent endothelial lipase inhibitor with IC50 of 16 nM. GSK264220A has the potential to decrease the risk of cardiovascular disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 685506-42-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-103372. | |
| GSK 264220A | GSK 264220A. Group: Biochemicals. Grades: Purified. CAS No. 685506-42-7. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK2643943A | GSK2643943A is a deubiquitinating enzyme (DUB) inhibitor targeting USP20. GSK2643943A has affinity with an IC50 of 160 nM for USP20/Ub-Rho. GSK2643943A has anti-tumor efficacy and can be used for the research of oral squamous cell carcinoma (OSCC) [1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2449301-27-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111458. | |
| GSK2656157 | GSK2656157 is a selective and ATP-competitive inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) with an IC50 of 0.9 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1337532-29-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13820. | |
| GSK269962A | GSK269962A (GSK 269962) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A has anti-inflammatory and vasodilatory activities[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: GSK 269962. CAS No. 850664-21-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg; 500 mg; 1 g. Product ID: HY-15556. | |
| GSK-2793660 | GSK-2793660 is an orally active and irreversible inhibitor of Cathepsin C (CTSC). GSK-2793660 can be used for the research of bronchiectasis[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1613458-78-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-112318A. | |
| GSK2795039 | GSK2795039 is a NADPH oxidase 2 (NOX2) inhibitor with a mean pIC50 of 6 in different cell-free assays. GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption[1].GSK2795039 reduces apoptosis[2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1415925-18-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18950. | |
| GSK2798745 | GSK2798745 is a potent, selective, and orally active transient receptor potential vanilloid 4 (TRPV4) ion channel blocker with IC50s of 1.8 and 1.6 nM for hTRPV4 and rTRPV4, respectively. GSK2798745 can be used in cardiac and respiratory diseases research[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1419609-94-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg. Product ID: HY-19765. | |
| GSK2801 | GSK2801, a chemical probe, is a potent, selective, orally active and cell active acetyl-lysine competitive BAZ2A and BAZ2B bromodomains inhibitor with Kd values of 136 nM and 257 nM, respectively. GSK2801 shows >50-fold selectivity for BAZ2A/B over BRD4[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1619994-68-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15658. | |
| GSK2807 Trifluoroacetate | GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of SMYD3, with a Ki of 14 nM and an IC50 of 130 nM[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2245255-66-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-104009A. | |
| GSK 2830371 | GSK 2830371 is a highly selective Wip1 phosphatase inhibitor with IC50 of 6 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1404456-53-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-15832. | |
| GSK2837808A | GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively. Uses: Scientific research. Category: Signaling pathways. CAS No. 1445879-21-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100681. | |
| GSK2850163 | GSK2850163 is a novel inhibitor of inositol-requiring enzyme-1 alpha (IRE1α) which can inhibit IRE1α kinase activity and RNase activity with IC50s of 20 and 200 nM, respectively. Uses: Scientific research. Category: Signaling pathways. Alternative Names: GSK163. CAS No. 2121989-91-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-U00459. | |
| GSK2879552 | GSK2879552 an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/ KDM1A), with potential antineoplastic activity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1401966-69-5. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 1 g. Product ID: HY-18632. | |
| GSK2879552 dihydrochloride | GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1902123-72-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18632A. | |
| GSK2879552 Dihydrochloride | GSK2879552 2HCl is a potent, selective, orally bioavailable, irreversible LSD1 inhibitor with Kiapp of 1.7 μM. Phase 1. Group: Inhibitors. CAS No. 1902123-72-1. Pack Sizes: 5mg. Product ID: S7796. Formula: C23H28N2O2.2HCl. Smiles: C1CN(CCC1CNC2CC2C3=CC=CC=C3)CC4=CC=C(C=C4)C(=O)O.Cl.Cl. Storage Conditions: 2 years -80 in solvent. | United States; Europe |
| GSK-2881078 | GSK-2881078, an indole derivative, has been found to be an androgen receptor modulator that could probably be effective against Cachexia. It is still under Phase I trail. Uses: Anabolic agents. Alternative Names: GSK 2881078; GSK2881078; CS-5736; (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile. Grades: 98%. CAS No. 1539314-06-1. Molecular formula: C14H13F3N2O2S. Mole weight: 330.33. | |
| GSK-2881078 | GSK-2881078 is an orally active and nonsteroidal selective androgen receptor modulator (SARM) which act as partial AR agonists in androgenic tissues while mainly as complete AR agonists in synthetic metabolic tissues,induces AR-mediated transcriptional activation in PC3(AR)2 cells (EC50 = 3.99 nM) and the effect can be inhibited by the non-steroidal AR antagonist Bicalutamide. GSK-2881078 can be used in research of muscle weakness and cachexia associated with both chronic and acute illness[1][2][3][4]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1539314-06-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100186. | |
| GSK2982772 | GSK2982772 is a potent, orally active and ATP competitive RIP1 kinase inhibitor with IC50 values of 16 nM and 20 nM for human and monkey RIP1, respectively[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1622848-92-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101760. | |
| GSK2982772 | GSK2982772, with potential effect to treat inflammatory diseases, potently binds to RIP1 with exquisite kinase specificity. In phase 2a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis. Alternative Names: GSK2982772; GSK 2982772; GSK-2982772; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide. CAS No. 1622848-92-3. Molecular formula: C20H19N5O3. Mole weight: 377.4. | |
| GSK2983559 active metabolite | GSK2983559 active metabolite is an active metabolite of GSK2983559. GSK2983559 active metabolite is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1. Uses: Scientific research. Category: Signaling pathways. CAS No. 1423186-80-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19764. | |
| GSK 3008348 | GSK 3008348 is a small molecule antagonist of integrin αvβ6 with IC50 values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 can be used for research on pulmonary fibrosis and various types of cancer[1][2][3][4]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1629249-33-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 1 g. Product ID: HY-19767. | |
| GSK 3008348 hydrochloride | GSK 3008348 hydrochloride is a small molecule antagonist of integrin αvβ6 with IC50 values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 hydrochloride can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 hydrochloride prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 hydrochloride can be used for research on pulmonary fibrosis and various types of cancer[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1629249-40-6. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19767A. | |
| GSK3117391 | GSK3117391 (ESM-HDAC391; CHR-5154; HDAC-IN-3) is an orally active HDAC inhibitor with a IC50 of 55 nM. Using esterase-sensitive motif technology, GSK3117391 is selectively converted into its active acid metabolite HDAC189 in cells expressing carboxylesterase-1. GSK3117391 induces sustained global protein acetylation in monocytes, inhibits the production of proinflammatory cytokines, depletes circulating monocytes, downregulates the expression of CSF1R, and inhibits monocyte adhesion and differentiation. GSK3117391 can be used in the research of chronic inflammatory diseases[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ESM-HDAC391; CHR-5154; HDAC-IN-3. CAS No. 1018673-42-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19772. | |
| GSK-3174998 | GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2089398-68-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P991052. | |
| GSK319347A | GSK319347A is a dual inhibitor of TBK1 and IKKε with IC50s of 93 nM and 469 nM, respectively. GSK319347A also inhibits IKK2 with an IC50 of 790 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 862812-98-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-14682. | |
| GSK321 | GSK321 is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. GSK321 induces decrease in intracellular α-Hydroxyglutaric acid (2-HG) (HY-113038B), abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. GSK321can be used for research of acute myeloid leukemia (AML) and other cancers[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1816331-63-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18948. | |
| GSK3326595 | GSK3326595, also called as EPZ015938, is an orally available and specific inhibitor of protein arginine methyltransferase 5 (PRMT5) that potently inhibits tumor growth in vitro and in vivo in animal models and has entered clinical trials for the treatment of solid tumors and non-Hodgkin's lymphoma. Alternative Names: GSK-3326595; GSK 3326595; GSK3326595; EPZ015938; EPZ 015938; EPZ-015938; 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]pyrimidine-4-carboxamide. CAS No. 1616392-22-3. Molecular formula: C24H32N6O3. Mole weight: 452.55. | |
| GSK3326595 | GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma[1][2][3][4][5]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: EPZ015938. CAS No. 1616392-22-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg; 1 g. Product ID: HY-101563. | |
| GSK3326595 (Pemrametostat, EPZ015938) | Pemrametostat (GSK3326595, EPZ015938) is an orally active, potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) and potently inhibits tumor growth in vitro and in vivo in animal models. Group: Inhibitors. Alternative Names: EPZ015938. CAS No. 1616392-22-3. Pack Sizes: 5mg. Product ID: S8664. Formula: C24H32N6O3. Smiles: CC(=O)N1CCC(CC1)NC2=NC=NC(=C2)C(=O)NCC(CN3CCC4=CC=CC=C4C3)O. Storage Conditions: 2 years -80 in solvent. | United States; Europe |
| GSK3368715 | GSK3368715 (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 (EPZ019997) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: EPZ019997. CAS No. 1629013-22-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-128717. | |
| GSK3368715 dihydrochloride | GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: EPZ019997 dihydrochloride. CAS No. 1628925-77-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-128717A. | |
| GSK343 | GSK343, a chemical probe, is a highly potent and selective EZH2 inhibitor with an IC50 of 4 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1346704-33-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13500. | |
| GSK-3484862 | GSK-3484862 is a non-covalent inhibitor for DNA methyltransferase (Dnmt1). GSK-3484862 induces DNA hypomethylation to against cancer. GSK-3484862 mediates dramatic demethylation in murine embryonic stem cells with minimal non-specific toxicity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2170136-65-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 500 mg; 1 g. Product ID: HY-135146. | |
| GSK360A | GSK360A is a potent and orally active HIF-PHD inhibitor with IC50 values of 10, 100, and 126 nM for PHD1, PHD2, and PHD3, respectively. GSK360A activates the HIF-1 alpha pathway and protect the failing heart after myocardial infarction (MI) [1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 931399-19-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-123422. | |
| GSK 366 | GSK 366 is a type II kynurenine-3-monooxygenase (KMO) inhibitor with IC50 values of 2.3 nM and 0.7 nM for human KMO and P. fluorescens-KMO (Pf-KMO). GSK 366 binds to KMOs substrate site, prevents productive NADPH association, substrate binding, and FAD hydroperoxy species formation. GSK 366 does not stimulate hydrogen peroxide (H2O2) production and reduces H2O2 levels. GSK 366 can be used for the researches of inflammation and neurological disease, such as acute pancreatitis multiple organ dysfunction syndrome and Alzheimers disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1953157-39-5. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-119171. | |
| GSK-3685032 | GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2170137-61-6. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139664. | |
| GSK3787 | GSK3787 is a selective and irreversible peroxisome proliferator-activated receptor δ (PPARδ) antagonist with pIC50 of 6.6. Uses: Scientific research. Category: Signaling pathways. CAS No. 188591-46-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15577. | |
| GSK 3787 | GSK 3787. Group: Biochemicals. Grades: Purified. CAS No. 188591-46-0. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
Our database is helping our users find suppliers everyday.
